MMP9 and plasma cell myeloma: Similarly, EVs derived from aggressive myeloma patient cells, which bound to both RPMI-8226 plasmacytoma lymphocytes and human endothelial cells via surface-associated fibronectin, increased the expression of MMP-9 in the RPMI-8226 cells and promoted endothelial cell invasion.